<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904680</url>
  </required_header>
  <id_info>
    <org_study_id>Psoriasis</org_study_id>
    <nct_id>NCT03904680</nct_id>
  </id_info>
  <brief_title>Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients</brief_title>
  <official_title>Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of cardiovascular risk in psoriasis has been reported in previous
      studies.Various studies have also shown that systemic treatments for psoriasis, including
      methotrexate, may significantly decrease this cardiovascular risk. We proposed that the
      addition of vitamin D may not only improve the therapeutic effect of various treatment
      modalities but also increase its effect on decreasing the cardiovascular risk in psoriasis.
      So our aim of work is to assess the Clinical improvement and cardiovascular risks in
      psoriatic patients after treatment with methotrexate alone with the dose of 0.2-0.5
      mg/kg/week for three months in comparison to combined methotrexate with the same dose and
      vitamin D injection with the dose of 200,000 IU per month for 3 months.

      Each patient will do the following before starting treatment&amp; after 3 months:

        1. Fasting blood sugar, 2 hours postprandial and glycosylated hemoglobin

        2. Liver and Kidney function tests.

        3. Cardiovascular risk assessment by measuring the intima media thickness of carotid
           arteries using Carotid duplex and High sensitive C reactive protein measuring by
           particle-enhanced immunonephelometry on autoanalyzer.

        4. Lipid profile (HDL, LDL, cholesterol and triglycerides).

        5. Calculate body mass index and measure blood pressure

        6. Albumin /creatinine ratio

        7. Serum vitamin D level. Clinical response will be evaluated by Psoriasis Area and
           Severity index (PASI) &amp; Psoriasis Disability Index (PDI) scores before and after 3
           months of treatment
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be randomly divided into 2 groups:
Group A: 15 patients will take methotrexate weekly for 3 months for the treatment of psoriasis.
Group B: will take methotrexate weekly in addition to Vitamin D injections monthly for 3 months for treatment of psoriasis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intima Media thickness of carotid arteries from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Intima Media thickness of left and right common carotid arteries, bulb of common carotid arteries and internal carotid arteries as measured by carotid duplex before starting the treatment and after 3 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in high sensitive C- Reactive protein from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in high sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation, after 3 months of treatment from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area and Severity index change (PASI)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in PASI after 3 months of treatment from baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate and Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients will take methotrexate weekly with the dose of 0.2-0.5 mg/kg/week and Vitamin D intramuscular injections with the dose of 200,000 IU per month for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate 2.5 mg tablet</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>Methotrexate and Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D 200,000 IU ampules</description>
    <arm_group_label>Methotrexate and Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Psoriasis patient not on systemic treatment at least for 3 months before inclusion in
             the study

          -  PASI &gt;10

        Exclusion Criteria:

          -  Patients with autoimmune diseases.

          -  Patients with liver disease or kidney diseases

          -  Patients with Diabetes mellitus

          -  Females in child bearing period not using methods of contraception

          -  Any associated dermatological disease

          -  Evidence of infection

          -  Pregnancy and lactation

          -  Patients taking vitamin D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eman R Said, MD</last_name>
    <phone>+201110066044</phone>
    <email>dremy07@cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed HM El-Komy, MD</last_name>
    <email>komy_m@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Furue M, Tsuji G, Chiba T, Kadono T. Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin. Intern Med. 2017;56(13):1613-1619. doi: 10.2169/internalmedicine.56.8209. Epub 2017 Jul 1. Review.</citation>
    <PMID>28674347</PMID>
  </reference>
  <reference>
    <citation>Fu LW, Vender R. Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome. Dermatol Res Pract. 2011;2011:276079. doi: 10.1155/2011/276079. Epub 2011 Jun 5.</citation>
    <PMID>21747838</PMID>
  </reference>
  <reference>
    <citation>Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol. 2019;38(1):33-54. doi: 10.1080/08830185.2018.1539084. Epub 2018 Nov 20. Review.</citation>
    <PMID>30457023</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Eman Raafat Said</investigator_full_name>
    <investigator_title>Lecturer of Dermatology Department, Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

